Part 1: The Role of TL1A in IBD
2:20
Part 1: The Role of TL1A in IBD
1 month ago
YouTubeVindico Medical Education
Evolving Methods for Precision Care in IBD Management and Targeting TL1A
55:00
Evolving Methods for Precision Care in IBD Management and Targeting TL1A
578 views11 months ago
YouTubePeerView CME
TL1A Expression in Human IBD and Animal Models - SlideServe
TL1A Expression in Human IBD and Animal Models - SlideServe
Jul 22, 2014
slideserve.com
Part 2: Inhibiting TL1A to Treat IBD
2:35
Part 2: Inhibiting TL1A to Treat IBD
1 month ago
YouTubeVindico Medical Education
UChicago Advances IBD Trials With Focus on Microbiome and Access | HCPLive
UChicago Advances IBD Trials With Focus on Microbiome and Access | HCPLive
2 months ago
hcplive.com
Diane Mathis (Harvard) 1: An Introduction to T Cell Tolerance
36:40
Diane Mathis (Harvard) 1: An Introduction to T Cell Tolerance
40.5K viewsMar 1, 2017
YouTubeScience Communication Lab
New Anti TL1A Antibody Could Transform Crohn’s Disease Treatment #shorts
0:54
New Anti TL1A Antibody Could Transform Crohn’s Disease Treatment #shorts
181 views6 months ago
YouTubeV Creatives
1:11:10
IBD系列 - 立足炎症与纤维化交汇机制：TL1A 抑制疗法的应用前景 2026
63 views2 weeks ago
bilibiliJames在北京
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
Feb 20, 2024
marketscreener.com
24:18
自己免疫疾患関連マウスモデル：最新の進歩と応用
35 views11 months ago
YouTubeバイオサイトジェン
3:42
Epithelial alarmin TL1A is a co-factor of IL-33
615 viewsApr 10, 2024
YouTubeJournal of Experimental Medicine
Merck & Co., Inc.: Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
Sep 26, 2024
finanznachrichten.de
17:46
The Edge of a New Frontier: Anti-TL1A Monoclonal Antibodies for Ulcerative Colitis
467 viewsFeb 21, 2025
YouTubeAmCollege Gastro
0:36
PMC BREAKING | 17.1亿美元！艾伯维引进明济生物临床前TL1A单抗
243 viewsJun 14, 2024
bilibili医药魔方
16:48
Cell-Mediated (Cellular) Immunity [aka T-cell immunity] - Physiology & Immunology
190.9K viewsDec 25, 2021
YouTubeMedicosis Perfectionalis
Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
May 13, 2025
finanznachrichten.de
Xencor annonce des résultats intermédiaires positifs de la première étude chez l'homme sur Xmab942, un anticorps anti-Tl1a à haute puissance et à demi-vie prolongée, en cours de développement pour le traitement des maladies inflammatoires de l'intestin.
Apr 29, 2025
zonebourse.com
Vial Initiates Phase 1 Trial of Anti-TL1A Antibody | Thomas McAlear, PhD
6 months ago
linkedin.com
1:01
Cell Signaling Overview Animation
27.3K viewsJun 15, 2022
YouTubeHeather Scherr
2:19
For patients with moderately to severely active ulcerative colitis, the efficacy and safety of the anti-TL1A monoclonal antibody tulisokibart is unknown. Results of a phase 2 trial are summarized in a new Quick Take video. https://nej.md/4gCAts6 | The New England Journal of Medicine
1.8K viewsSep 29, 2024
FacebookThe New England Journal of Medicine
19:31
#MondayNightIBD IBD Clinical Trials to Watch: Anti-TL1As & mir124 enhancers
506 views8 months ago
YouTubeBonum Continuing Education
Spyre Therapeutics administre la première dose à un patient dans l'essai de phase 2 SKYway, une étude pionnière de l'anticorps anti-TL1A SPY072 dans les maladies rhumatismales
8 months ago
zonebourse.com
Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
Jan 8, 2024
marketscreener.com
9:41
Common cell signaling pathway
849.9K viewsOct 14, 2020
YouTubeOsmosis from Elsevier
2:42
Is TL1A a Cytokine That Is Involved in Arthritis Inflammation? | Rheumatoid Arthritis Wellness Guide
17 views9 months ago
YouTubeRheumatoid Arthritis Wellness Guide
Teva Pharmaceutical Industries Ltd: Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease
Feb 22, 2025
finanznachrichten.de
1:01:50
Role of TL-1A/DR3 in Intestinal Inflammation
1.2K viewsFeb 9, 2018
YouTubeFralin Biomedical Research Institute
31:32
IBD - its drugs and recent advances
3 views1 month ago
YouTubeMedicosphere
Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
11 months ago
finanznachrichten.de
19:35
Operative Strategies in Inflammatory Bowel Disease (IBD)
35.7K viewsDec 6, 2019
YouTubeJohns Hopkins Medicine
See more
Static thumbnail place holder